Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Ex Vivo Gene Therapy for Epidermolysis Bullosa: Progress, Safety, and PZ Cell
Description
The speaker, a dermatology professor, explains ex vivo gene therapy for epidermolysis bullosa (EB), distinguishing it from in vivo approaches and outlining key design choices such as viral vector, target cell, and delivery route. She reviews major safety concerns, including insertional mutagenesis, immune responses, and the possibility of autoantibodies, and notes how early success and risk assessments informed interactions with the FDA. The talk highlights landmark ex vivo studies in junctional EB that restored laminin-332 or corrected keratinocytes, showing long-term clinical benefit and minimal adverse events. The main focus is PZ Cell (beremagene geperpavec, ZEVASKYN), an FDA-approved retroviral, ex vivo keratinocyte gene therapy for recessive dystrophic EB that is manufactured from patient biopsies into graft sheets and applied surgically at qualified centers. She describes wound types in RDEB, the trial endpoints emphasizing at least 50% healing and pain reduction, and reports strong efficacy in phase 1/2a and phase 3 trials, with durable healing over years and meaningful pain improvement. Safety data showed no serious treatment-related adverse events, no systemic replication-competent retrovirus, transient localized immune complexes only, and no PZ Cell-related squamous cell carcinoma. She also outlines the practical treatment workflow, including insurance authorization, biopsy, product manufacturing, preoperative optimization of nutrition, anemia, and wound care, surgical graft placement, hospitalization, and recovery. Finally, she briefly mentions another ex vivo approach using lentiviral correction of fibroblasts for DEB that has shown promising early results and is in phase 3 testing.
View moreConclusions
- Ex vivo gene therapy for epidermolysis bullosa can produce durable clinical benefit by correcting patient cells outside the body and grafting them back onto affected skin.
- Skin-targeted gene therapy appears to have a favorable safety profile overall, with no clear signal of serious insertional mutagenesis, systemic retroviral spread, or treatment-related skin cancer in these studies.
- Immune responses to restored collagen VII are possible but, in the reported trials, were generally limited and transient rather than causing major systemic complications.
- Autologous keratinocyte grafts corrected with retroviral vectors can achieve long-lasting healing in junctional EB, with benefits persisting for years and little evidence of late adverse effects.
- Pz-cel/Zevaskyn provides meaningful wound improvement in recessive dystrophic EB, especially for chronic wounds that are otherwise unlikely to heal.
- In the randomized phase 3 trial, pz-cel outperformed standard care on both wound healing and pain reduction, supporting its clinical efficacy.
- The treatment’s main burden is logistical and procedural rather than biological, requiring specialized centers, biopsy-based manufacturing, surgery, hospitalization, and substantial insurance and cost hurdles.
- Long-term follow-up suggests that a substantial proportion of treated sites maintain at least partial healing for years after pz-cel grafting.
- Fibroblast-based ex vivo gene therapy with dabocemagene autoficel also shows promising wound-closure results in RDEB and may become another viable approach.
- Overall, ex vivo gene therapy is emerging as a transformative treatment strategy for EB, with the best evidence currently supporting durable benefit in both JEB and RDEB while larger studies continue to refine safety, access, and durability.
- Gorell et al., Cold Spring Harb Perspect Med, 2014, 4(4).
- Hacein-Bey-Abina et al., Science 2003.
- Hacein-Bey-Abina et al., N Engl J Med 2008.
- Cavazzana et al., Nature 2019.
- FDA Gene Therapy Guidance 2020.
- Nature Medicine report on LAMB3 retroviral vector in JEB (2005 Italy case).
- Journal of Investigative Dermatology report on LAMB3 retroviral vector in JEB (2014 Austria case).
- Regeneration of the entire human epidermis using transgenic stem cells.
- Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa — 5-Year Outcomes.#10.1056/nejmoa2108544
- Siprashvili et al., JAMA 2016.
- Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
- Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.#10.1186/s13023-022-02546-9
- Prademagene zamikeracel phase 3 VITAL trial, Lancet.
- Tang et al., Lancet 2025.
- Gaona et al., SID 2024.
- Gorell et al., Soc Ped Derm, 2024.
- Petrof et al., British Journal of Dermatology, 2013, 169(5).
- clinicaltrials.gov and BJD, 2013, 169(5).